Abstract Cancer cells acquire cell-autonomous capacities to undergo limitless proliferation and survival through the activation of oncogenes and inactivation of tumor suppressor genes. Nevertheless, the formation of a clinically relevant tumor requires support from the surrounding normal stroma, also referred to as the tumor microenvironment. Carcinoma-associated Wbroblasts, leukocytes, bone marrow-derived cells, blood and lymphatic vascular endothelial cells present within the tumor microenvironment contribute to tumor progression. Recent evidence indicates that the microenvironment provides essential cues to the maintenance of cancer stem cells/cancer initiating cells and to promote the seeding of cancer cells at metastatic sites. Furthermore, inXammatory cells and immunomodulatory mediators present in the tumor microenvironment polarize host immune response toward speciWc phenotypes impacting tumor progression. A growing number of studies demonstrate a positive correlation between angiogenesis, carcinoma-associated Wbroblasts, and inXammatory inWltrating cells and poor outcome, thereby emphasizing the clinical relevance of the tumor microenvironment to aggressive tumor progression. Thus, the dynamic and reciprocal interactions between tumor cells and cells of the tumor microenvironment orchestrate events critical to tumor evolution toward metastasis, and many cellular and molecular elements of the microenvironment are emerging as attractive targets for therapeutic strategies.
individual components, in particular endothelial cells, macrophages, and cancer-associated Wbroblasts, in promoting tumor growth and progression. While most cellular components of the immune system are capable of rejecting tumors, in practice they are enslaved by cancer cells to promote their growth and invasion. Thus, knowledge and control of the tumor microenvironment is becoming as important as the knowledge and control of the transformed cancer cells to better understand cancer biology and to devise novel therapeutic approaches (Albini and Sporn 2007) .
The Wrst evidence that non-cancerous tissue elements might aVect tumor formation and growth came from the Weld of inXammation. A link between inXammation and cancer has been recognized already in 1863 by Rudolf Virchow, when he reported the presence of leucocytes in tumor tissues (Balkwill and Mantovani 2001) . Based on this observation he proposed the idea that cancer originates at sites of chronic inXammation. The presence of leukocytes in tumors was subsequently interpreted as an aborted attempt of the immune system to reject the tumor. This observation remained largely neglected for over a century until it was demonstrated that innate immune cells, in particular phagocytes, play an active role in promoting the carcinogenesis process. In addition to leukocyte inWltration, angiogenesis is now being recognized as another stromal reaction promoting cancer progression. Thus, chronic inXammatory and neovascularization are critical, if not essential, for cancer progression (Rüegg 2006) .
InXammatory lesions preceding early stages of neoplastic progression contribute to create an environment favorable to cancer development. For example, chronic inXammatory bowel diseases (IBD), such a Crohn's disease or ulcerative colitis, or chronic reXux esophagitis in Barrett syndrome are associated with increased risk of developing colorectal or esophageal cancer, respectively (van der Woude et al. 2004 ). Cancers of infectious etiology have also been associated with chronic inXammation: for example, Hepatitis B and C viruses for hepatic cancer, Schistosomes for bladder cancer, and Helicobacter pylori for gastric cancer . In many epidemiological studies the role of chronic inXammation in the carcinogenesis process was examined through studies of pro-inXammatory and antiinXammatory cytokines along with other risk factors including virus-transmitted infections and genetic markers that take part in the inXammatory response. Experimentally, systemic administration of non-speciWc proinXammatory substances, like LPS, has been shown to favor tumor growth, angiogenesis and metastatic tumor spreading to secondary organs (Harmey et al. 2002) .
InXammation and tumor progression
Today some of the underlying cellular and molecular events connecting inXammation to cancer have been uncovered . Chronic inXammatory events create a local microenvironment capable of promoting tumor progression though a series of dynamic and Fig. 1 Heterotypic cellular interactions in the tumor microenvironment. a Tumor cells orchestrate directly (e.g. though the release of factors) or indirectly (though the induction of tissue hypoxia or appearance of necrosis) the modiWcation of the microenvironment by attracting or activating many non-tumoral cells, including blood and lymphatic endothelial cells and pericytes, carcinoma associated Wbroblast, bone marrow-derived cells, immune and inXammatory cells. Tumor cells can also deposit or modify the extracellular matrix. Most of these stromal modiWcations start early during tumor progression, often at the transition stage from premalignant to malignant lesions. In some cases they may even precede cancer formation, for example in situations of chronic inXammatory conditions. b In turn, tumor microenvironmental events promote tumor progression by stimulating tumor growth and survival, and facilitating invasion and metastasis. Collectively these events will contribute to determine the outcome of tumor progression: tumor growth, tumor dormancy, tumor invasion and metastasis and resistance to therapy. Abbreviations: B B lymphocyte; BMDC bone marrow-derived cells; BV blood vessel; CAF carcinoma associated Wbroblast; EC endothelial cell; ECM extracellular matrix; EMT epithelial to mesenchymal transition; Gr granulocyte; LEC lymphatic endothelial cell; LV lymphatic vessel; Mo monocyte; MSC mesenchymal stem cell; PC pericyte; T T lymphocyte; TAM tumor associated monocyte/macrophage; TC tumor cells reciprocal interactions between tumor cells and inXammatory cells (Coussens and Werb 2002) . Initially, tumor cells and cells of the tumor microenvironment, respond to tumor hypoxia and necrosis secondary to excessive tumor cell proliferation, by releasing a number of growth factors and cytokines that are chemoattractive for monocytes and macrophages, including colony stimulating factor (CSF)-1, granulocyte-monocyte (GM)-CSF, transforming growth factor (TGF)-, and chemokines (e.g. CCL2, CCL7, CCL3, CCL4) (Robinson and Coussens 2005) . In turn, recruited macrophages secrete growth factors that aVect tumor cell behavior (e.g. induction of motility), activate tumor endothelium and perpetuate inXammation (Allavena et al. 2008b) . Factors released by recruited monocytes/macrophages include vascular endothelial growth factor (VEGF)-A and -C, basic Wbroblast growth factor (bFGF), tumor necrosis factor (TNF), hepatocyte growth factor (HGF), epidermal growth factor (EGF) family members, plateletderived growth factor (PDGF), and chemokines such as CXCL12 and interleukin (IL)-8 (Benelli et al. 2006; Robinson and Coussens 2005) . Monocytes and macrophages also bring in much of the cyclooxygenase-2 (COX-2) present in the tumor environment. COX-2 expression and prostaglandins production within the tumor environment stimulate tumor cell proliferation, survival and motility but also tumor angiogenesis (Prescott and Fitzpatrick 2000) . Because of, COX-2 expression was long though to be restricted to inXammatory conditions, and potent COX-2 inhibitors (COXIBs) were available to treat inXammatory conditions, COX-2 appeared suddenly as a 'magic' therapeutic target for cancer prevention and treatment (Xu 2002) . However, the appearance cardiovascular complications induced by potent COXIBs (Dogne et al. 2006 ) has damped enthusiasm and hampered the widespread use of COXIBs for cancer chemoprevention.
The stroma of a full-blown tumor becomes inWltrated with many diVerent leukocyte populations, including neutrophils, eosinophils, basophils, monocytes/macrophages, dendritic cells, natural killer cells and lymphocytes (Lin and Pollard 2004) . Tumor inWltrating macrophages, also referred to as tumor educated or tumor-associated macrophages (TAM), are known residents in most neoplastic tissues, where they play a critical role in orchestrating and promoting tumor growth (Allavena et al. 2008b; Pollard 2004) . DeWcient monocyte recruitment at tumor sites in mice lacking CSF-1 expression was shown to attenuate late-stage progression and metastasis formation, suggesting that monocytes contribute to tumor progression (Lin et al. 2001) . A positive correlation between the number of TAMs and poor prognosis has been reported for many cancers. Importantly, monocytes/macrophages are often present already at the very early stage of tumor development, in close associations with areas of hyperplasia and atypia (Mantovani et al. 2006; Pollard 2004 ). This observation further reinforces the notion that macrophages themselves are driving force contributing to tumor initiation and/or initial tumor progression. Once recruited to tissue sites, monocytes can assume diVerent phenotypes, epitomized by the M1 and M2 phenotypes, based on local environmental stimuli . The M1 phenotype is associated with inXammation and microbial killing activity, whereas the M2 phenotype is associated with tissue remodeling and pro-angiogenic activities. The latter are predominant and crucial events in cancer. Macrophage-tumor cell interaction leads to the release of macrophage-derived cytokines, chemokines and growth/motility factors (e.g. GM-CSF, IL-8, EGF) which in turn promote the recruitment of additional inXammatory cells, thereby amplifying the inXammatory reaction within the tumor microenvironment (Balkwill 2004) . Chemokines play an important role in coordinating the stromal response to cancer, including the polarization of the immune responses to the tumor, the determination of the composition of the cellular inWltrate, and the induction of angiogenesis. Chemokine receptors have been detected on cancer cells and the relevant ligands were found expressed at the primary tumor site and at sites of tumor metastasis, suggesting a direct role for chemokines/chemokine receptors in tumor growth and metastasis (Balkwill 2004) .
InXammatory insults lead to upregulation of non-speciWc pro-inXammatory cytokines such as IL-1 / , IL-6, interferon (IFN)-and TNF (Aggarwal et al. 2006; Robinson and Coussens 2005) . Such unresolved chronic inXammation is associated with increased conversion of normal cells to preneoplastic foci. Accumulation of somatic mutations with gain of function can change preneoplastic foci into foci of fully transformed cells with tumor initiation capacities. Activated nuclear factor-kappa B (NF-B) transcription factor, is one of the main link between inXammation and tumorigenesis and may be key in allowing both preneoplastic and malignant cells to escape apoptosis (Karin 2006; Naugler and Karin 2008) . In addition to macrophages, mast cells and neutrophils can also support tumor progression by sustaining inXammation and secreting tumor-promoting cytokines, growth factors and proteases. For example, in skin carcinogenesis models, granulocytes were identiWed as source of MMP-9 expression required for tumor development (Coussens et al. 2000) . Consistent with this observation, it has been recently reported that neutrophils also play a key role in ras oncogene-driven tumor progression (Ji et al. 2006) .
InXammatory cytokines may act as an initiator and promoter of carcinogenesis by directly increasing proliferation of epithelial cells. InXammation may also promote tumorigenesis indirectly, by modulating the phenotype and function of cells mediating speciWc or innate immunity (Rollins 2006 In spite of the important recruitment of inXammatory cells in the tumor microenvironment, these cells do not represent the major cell population of the tumor stroma (Tlsty and Coussens 2006) . Carcinoma-associated Wbroblasts (CAFs) are the most abundant cells of the tumor microenvironment (Orimo et al. 2005; Orimo and Weinberg 2006) . CAFs are usually recognized by the expression of -smooth muscle actin (a-SMA), similar to myoWbroblasts present at the site of wound healing and chronic inXammation, which is absent in normal dermal Wbroblasts. CAFs might diVerentiate locally from normal stromal Wbroblasts of the surrounding tissue or from bone marrow-derived mesenchymal stem cells recruited to the tumor. The observation that CAFs lack genetic mutation or aneuploidy typically found in the neighboring tumor cells, tend to exclude a possible tumor origin of these cells following complete epithelial to mesenchymal transition (EMT) (Kalluri and Zeisberg 2006) .
The immune system and its role in tumor progression
In the early 1900 Paul Ehrlich proposed the notion that the immune system could be exploited therapeutically to treat tumors by suggesting the use of antibodies to deliver toxins to tumor cells (immunotoxis as 'magic bullets') (Strom et al. 1990 ). Although in practice it has proven diYcult to create safe and eVective 'magic bullets', we have nevertheless learned that both innate and adaptive immune responses can both promote tumor progression or mediate tumor rejection, as a balance between pro-tumor and antitumor immunity (Ostrand-Rosenberg 2008) . In the tumor microenvironment the cellular components of the inXammatory inWltrate and immunomodulatory mediators (cytokines and chemokines), polarize host immune response toward a speciWc phenotype, in favoring or suppressing tumor progression (DeNardo and Coussens 2007; Johansson et al. 2008) . It is nowadays considered that the main mechanism of tumor immunity is due to an antitumoral T cell response ). This antitumor response can be due to the direct killing of tumor cells by CD8 cytotoxic T lymphocytes (CTL) recognizing major histocompatibility complex (MHC) class I restricted antigens expressed on the surface of tumor cells. Oligoclonal tumor-reactive CTLs can be detected in the blood or among tumor inWltrating lymphocytes (TILs) in cancer patients. In some cases the presence of TILs in primary tumors is associated with a better prognosis, suggesting that TILs might control tumor growth (Yu and Fu 2006) . However, in most cases the adaptive immune response against tumor cells is very weak and largely ineYcient, since the tumor itself and the surrounding microenvironment down-regulate CTL responses (tumor induced immunosuppression). The fact that CTLs against human and animal tumors can be easily generated in vitro using freshly isolated peripheral blood lymphocytes indicate that the tumor microenvironment has immunosuppressive capacities Verdegaal et al. 1999) .
Evidence for the existence of a speciWc antibody response against tumor cells in cancer patients stems from the observation that sera from some tumor patients speciWcally recognize antigens selectively expressed on autologous tumor cells but not on autologous normal cells. Recently, using the serological analysis of recombinantly expressed tumor antigens, a large number of tumor antigens have been identiWed from the antibody repertoire of cancer patients. Antitumor antibodies have been detected against many intracellular antigens, including p53 in patients with melanoma, hepatocellular carcinoma, colorectal and breast cancers, and against membrane-associated antigens, such as Her-2 in patients with breast and prostate cancer (Mittelman et al. 2002) . Strikingly, the cellular localization of the recognized antigen has prognostic relevance. Antibodies detected against intracellular proteins appear to be correlated with poor prognosis, while antibodies reactive against cell surface components appear to be correlated with a better prognosis (Taylor and Gercel-Taylor 1998) .
It is generally assumed that growing tumors develop strategies to evade or limit the eVects of the host's immune responses (Drake et al. 2006 ). These assumptions are based on the evidence that an eYcient tumor-speciWc immune response is rarely detectable in patients and that tumor progression is often associated with the secretion of immunosuppressive factors and down-regulation of MHC class I antigen presentation. Furthermore, as suggested by Gilboa, increasing immune activity against a tumor in any active or passive immunotherapy will exacerbate the rate of immune escape and select for a tumor sub-population, which will be resistant to immunotherapy. Immune escape can be broken down into several mechanisms, including down-regulation or loss of tumor-associated antigens (TAA), or the release of immunosuppressive cytokines (Gilboa 1999) . Loss of TAA expression is one of the main mechanisms by which tumors escape CTL recognition in vivo. Since intratumoral TAA expression frequently appears to be heterogeneous, the emergence of antigen-loss variants due to selection pressure mediated by a relevant antitumor response induced by a vaccination strategy is to be expected. The secretion of immunosuppressive cytokines and chemokines into the tumor microenvironment, such as TGF-, IL-6 and IL-10, which can interfere with multiple steps and pathways in the generation of an eVective immune response, has been described in many types of tumors ). In particular, TGF-is an extremely potent immunosuppressive factor that aVects proliferation, activation and diVerentiation of the immune eVector cells and has been associated with malignant progression (Teicher 2001) . The presence of this factor also inhibits the production of immunoregulatory cytokines and may also modify the expression of surface receptors essential for T cell activation and growth. Concomitantly, TGF-is a potent inducer of EMT and contributes to promote the invasive and metastatic behavior of tumor cells (Bierie and Moses 2006b; Lee et al. 2006 ). IL-6 is expressed in the tumor microenvironment in 83% of patients with colorectal carcinoma correlates with unfavorable disease progression (Piancatelli et al. 1999 ). IL-6 is also known to have multiple eVects on T cell function, and it may play a signiWcant role in modulating T cell reactivity at the tumor site. Recently, has been reported the IL-6/IL-8 interleukindependent inXammatory network contributes to connecting oncogene-induced cellular senescence, with an inXammatory phenotype and tumor progression (Kuilman et al. 2008 ). In particular IL-6 acts as a central regulator of this inXammatory network, also mediates cellular senescence, reminding a striking parallel with TGF- (Bierie and Moses 2006a) . Both cytokines are able to restrain proliferation of non-malignant cells present in the tumor microenvironment, but at the same time they promote proliferation, invasion and metastasis, thereby reinforcing the close connection between inXammatory mediators and neoplastic progression.
IL-10 has pleiotropic eVects on T cell functions, including the suppression of GM-CSF, IFN-and IL-2 production by T helper cells, inhibition of T cell proliferation, downregulation of expression of adhesion molecules and MHC class I and class II antigens (Mocellin et al. 2005) . Patients with ovarian carcinoma frequently present abundant levels of this cytokine in serum, in the peritoneal exudate and in the tumor tissue. These cytokines inhibit the expression of immune activating cytokines, such as IL-2 and IL-4 (Benelli et al. 2006; Punnonen et al. 1998) . This can inhibit the natural homeostatic mechanisms that control the speciWc cellular immunity and could be responsible for the signaling defects in T lymphocytes, routinely observed in late stage cancer patients, rendering them ineVective in mounting a TAA speciWc eVector activity.
Tumor angiogenesis
Angiogenesis occurs in physiological conditions during embryonic development, wound healing and tissue regeneration (Carmeliet 2005) . In these circumstances, angiogenesis is a highly regulated process leading to structured, hierarchically organized and well functioning vascular networks. In contrast, in pathological conditions such as cancer or chronic inXammation, angiogenesis leads to the formation of disorganized, chaotic and poorly functioning vascular networks (McDonald and Choyke 2003) . The formation of a tumor-associated (angiogenic) vasculature is a stromal reaction essential for tumor progression (Carmeliet and Jain 2000; Kerbel 2008 ). Tumor-associated vessels promote tumor growth by providing oxygen and nutrients and favor tumor metastasis by facilitating tumor cell entry into the circulation. In the absence of suYcient vascularization most tumors cannot exceed a few mm 3 in volume, and remain clinically silent (Folkman 1995) . Tumor angiogenesis is initiated at discrete time points during tumor progression ('angiogenic switch'), which are determined by the balance between the genetic status of the tumor itself, signals from stromal and recruited inXammatory cells and by the appearance of hypoxia (Bergers and Benjamin 2003; Coussens and Werb 2002) . The angiogenic switch often occurs at the time of the conversion from premalignant to malignant lesions (Hanahan and Folkman 1996) .
Angiogenesis is a multi step process involving diVerent cell types, in particular endothelial, perivascular cells (i.e. pericytes, smooth muscle cells), inXammatory and stromal cells. The cellular and molecular mechanisms of angiogenesis have been largely uncovered in recent years (Carmeliet 2000) . In order to form new vessels, endothelial cells have to exit dormancy, proliferate, migrate, diVerentiate, polarize and organize themselves into new tubular structures within the remodeled stroma. These events are induced and regulated by diVusible growth and chemotactic factors, cell adhesion receptors, and instructive molecules. Many molecular mediators and regulators of angiogenesis are now known. VEGFs have emerged as critical mediators of angiogenesis (Ferrara 2005) . The principal member of the VEGF family of factors, VEGF-A binds to and activates two tyrosine kinase receptors, VEGFR-1 and VEGFR-2. Of the two, VEGFR-2 is the major mediator of the mitogenic, angiogenic and permeability-enhancing eVects of VEGF. The signiWcance of VEGFR-1 in the regulation of angiogensis is more complex (Shibuya 2001) . Under some circumstances, the higher aYnity VEGFR-1 may function as a 'decoy' receptor that sequesters VEGF and prevents its interaction with VEGFR-2. Alternatively, VEGFR-1 may regulate function of VEGFR-2 (cross talk). There is growing evidence that VEGFR-1 has signiWcant roles in haematopoiesis and in the recruitment of monocytes and other bone-marrow-derived cells that may home in on the tumor vasculature and promote angiogenesis. VEGFR-1 is involved in the induction of matrix metalloproteinases (MMPs) and in the release of matrix-bound growth factors. Furthermore, in some cases VEGFR-1 is expressed by tumor cells and may mediate a chemotactic signal, thus potentially extending the role of this receptor in cancer growth (Gerber and Ferrara 2003) .
VEGF is strongly induced by hypoxia forming within the tumor microenvironment. The transcription factor hypoxia inducible factor (HIF) 1 plays a central role in the hypoxic regulation of VEGF (Semenza 2002) . HIF1 is constitutively produced in excess but rapidly degraded under normoxic conditions. The von Hippel-Lindau (VHL) tumor suppressor protein targets it for ubiquitination and subsequent proteasomal degradation (Semenza 2001) . In situ hybridization studies demonstrate that VEGF mRNA is expressed in many tumors. Renal cell carcinomas have a particularly high level of VEGF expression, consistent with the notion that inactivating VHL mutations occur in about 50% of such tumors, thus providing a further explanation for the responsiveness of this tumor type to a VEGF blockade (Haase 2006) . Strikingly, HIFs have been shown to activate speciWc signaling pathways such as Notch and Oct4 that control stem cell self renewal and multipotency, suggesting a possible link between hypoxia and stemness (Keith and Simon 2007) . Hypoxia, however, is not the only mechanism regulating VEGF expression in tumors. A broad and diverse spectrum of oncogenes can induce VEGF expression, including mutant ras, erbB-2/Her2, activated EGF receptor and bcr-abl. Besides VEGF, other vascular growth factors, including b-FGF, IL-8, TGF-, TNF and molecules promoting, mediating or regulating angiogenesis, have been identiWed and characterized in recent years. They include adhesion molecules of the integrin and cadherin families, such as V 3, 5 1, and VE-cadherin; extracellular matrix proteins, such as Wbronectin, collagens, and laminins; remodeling and morphogenic molecules and their receptors, in particular Angiopoietins/Ties, Notch and Delta-like ligands, Eph and Ephrins, semaphorins, neuropilins and the plexins; proteinases such as MMP-2 and -9, plasminogen activators (u-PA and t-PA) and their inhibitors (TIMPs and PAIs); intracellular signaling molecules, most notably protein kinases (e.g. raf and mitogen activated protein kinase (MAPK), protein kinase A (PKA), protein kinase B (PKB/Akt) and GTPases (e.g. Ras and Rho families), and many transcription factors and transcriptional regulators (besides HIF-1 ), such as inhibitors of diVerentiation (Id1/3), NF-B and homeobox gene products (e.g. Hox D3 and B3). The recent discovery that VEGFR-3 and its ligands VEGF-C and -D promote lymphatic vessel formation (lymphangiogenesis) has boosted research on tumor lymphangiogenesis (Alitalo and Carmeliet 2002) . Expression of VEGF-C or -D by tumor cells induces lymphatic vessel formation around the tumors and promotes metastatic tumor spreading at draining lymph nodes and distant organs. While it is clear that lymphatic vessels facilitate metastatic tumor spreading, the exact mechanism by which this occurs has not been fully elucidated (Alitalo et al. 2005 ).
InXammatory cells promote tumor angiogenesis
It is becoming increasingly evident that inXammatory cells recruited in the tumor stroma play a pivotal role in triggering tumor angiogenesis (Rüegg 2006; Shojaei et al. 2008) . It has been proposed that inXammatory cells might in fact be responsible for a substantial portion of tumor angiogenesis by acting as initiator of vascularization. Thus antiinXammatory drugs might be suitable tools in anticancer therapy. Innate immune (i.e. macrophages, neutrophils) release a number of factors able to stimulate and activate endothelial cells, such as VEGF, HGF, MMP-2, MMP-9 and IL-8. Neutrophils were largely ignored for a long time in the context of tumor angiogenesis but recent studies have shown their important role in this process (Coussens and Werb 2002) . Furthermore, the Human ImmunodeWciency Virus (HIV) viral transactivator protein Tat activates neutrophils as part of its angiogenic activity and angiostatin exerts its antiangiogenic activity, at least in part, through its interaction with neutrophils (Benelli et al. 2003) . The close relationship between inXammation and angiogenesis observed within tumors is likely due to the natural physiological relationship between these two compartments. Endothelial cells and cells of the immune/inXammatory system are derived from a common hematopoietic precursor cell (Dzierzak and Speck 2008) . Endothelial and immune cell are used to interact with each other, for example during leukocyte and lymphocyte traYcking across the endothelium and immune cells can aVect vascular functions. Many angiogenic factors inXuence the activity of immune cells that generally favor tumor survival and tolerance. Thus, in addition to the classical tumor-endothelium axis widely studied in the angiogenesis Weld, it emerges that inWltrating inXammatory cells favor the cross-talks between tumor cells and endothelial cells, thereby creating a tumor-inXammation-endothelium axis, which may open new therapeutic perspectives (Noonan et al. 2008; Shojaei et al. 2008 ). In addition, to classical inXammatory cells, bone marrow-derived cells (BMDC) has been recently shown to be mobilized from the bone marrow in response to stimuli originating form the growing tumor, and to recruit at tumor sites to promote tumor angiogenesis and tumor invasion. Furthermore, tumor-mobilized myeloid cells can also be directed to diVerent organs where they can form premetasitatic niches, which favor homing and survival of circulating tumor cells thereby promoting metastasis formation (Kaplan et al. 2006a ).
Antiangiogenic therapy is in clinical practice
In experimental models, inhibition of the angiogenic switch prevents progression of hyperplastic foci to in situ carcinoma, decreases cancer insurgence and reduces metastasis. Targeting tumor angiogenesis to inhibit tumor growth has now become a clinical reality. In pathological conditions, such as cancer, endothelial cells are constantly stimulated by angiogenic factors and fail to form a diVerentiated, mature and stable vascular network (Kerbel 2008) . Impinging on factors stimulating endothelial cells, results in the inhibition or even regression of angiogenic vessels (Ferrara and Kerbel 2005) . Conceptually, it has been proposed that therapeutic targeting of non-tumoral cells would circumvent the problem of drug resistance and selection of escape variants, since these cells are genetically stable (in contrast to tumor cells). Furthermore, one given antiangiogenic therapy would suit diVerent tumor types. Preclinical experiments and clinical studies demonstrated that reality is far more complex. In fact, the vast majority of drugs that were active in preclinical models failed to show eYcacy in clinical trials (Kerbel and Folkman 2002) . In spite of some initial negative clinical trials, major progress has been made over the past few years in targeting angiogenesis for human therapy, and inhibition of angiogenesis is now established as a new therapeutic approach to control tumor progression (Kerbel 2008) . To date four antiangiogenic drugs are in clinical use after approval by the Food and Drug Administration (FDA): Avastin (bevacizumab) ), a humanized anti-VEGF monoclonal antibody, for the treatment of metastatic colorectal cancer, in combination with chemotherapy, Nexavar (sorafenib) (Rini 2006) , Sutent (sunitinib) (Motzer et al. 2006) , two multi-tyrosine kinase inhibitors, and Torisel (temsirolimus) (Dancey 2005) , an inhibitor of the mammalian target of rapamycin (mTOR) kinase. These drugs showed to extend survival of patients with advanced cancers (Sessa et al. 2008) . Importantly, these compounds all target the VEGF pathway, either by inhibiting VEGF, its receptors or downstream molecules. Thus, to date the VEGF pathway is the best-characterized and validated therapeutic target to inhibit tumor angiogenesis for renal and gastrointestinal stromal tumors (GIST) (with Sorafenib and Sunitinib) without need for concomitant chemotherapy. In contrast, in lung, colorectal and breast cancers, survival beneWt is only observed when antiangiogenic drugs are administered in combination with chemotherapy (Jain et al. 2006; Sessa et al. 2008) Taken together, these achievements validated the concept that angiogenesis is a relevant therapeutic target in cancer. So far antiangiogenic drugs are being administered to patients with advanced cancers, and the impact on cancer progression and overall survival has remained small. It will be important to test whether antiangiogenic therapy administered in adjuvant settings may have a more signiWcant impact on the survival of patients at risk for relapse. Furthermore, recent experimental evidence indicates that tumors can develop resistance to antiangiogenic therapy (Bergers and Hanahan 2008) . This has been shown by inhibiting VEGF pathway and demonstrating that tumors resume angiogenesis by using alternative angiogenic factors, such as FGF-2 (Casanovas et al. 2005 ). It will be important to identify escape mechanisms of angiogenesis that could be targeted to improve eYcacy of current antiangiogenic treatments.
The tumor microenvironment as a niche favoring tumor cell survival and metastasis
Normal cells survive and grow within deWned environmental niches and are subjected to microenvironmental control. Outside of their speciWc niche, the tissue environment is hostile to normal cells. Since they lack necessary cell autonomous survival signals, normal cells will not survive an inappropriate microenvironment (Morrison and Spradling 2008) . Detachment-induced cell death (anoikis) has been proposed as the mechanism preventing normal cells from leaving their original environment and seeding at inappropriate locations (Chiarugi and Giannoni 2008) . In order to evade local tissue control and avoid anoikis during tumor development and progression, malignant cells start interacting with the surrounding extracellular matrix (ECM) (Reddig and Juliano 2005) . A bidirectional relationship is initiated between tumor cells and its surrounding stroma as a Wrst step to invasive growth on metastatic spreading (Bidard et al. 2008; Kopfstein and Christofori 2006; Weinberg 2008) . Stromal changes sustaining tumor progression include modiWcations of the extracellular matrix composition, activation of Wbroblasts, myoepithelial cells, and the recruitment of pericytes or smooth muscle cells and immune and inXammatory cells (Tlsty and Coussens 2006) .
In recent years, evidence accumulated suggesting that a small tumor cell subpopulation in the primary tumor mass might be responsible for tumor initiation, growth, maintenance and spreading. These cells, termed cancer stem cells or cancer initiating cells (CSC/CIC), represent a population with stem cell-like properties, in particular long-term survival, high self-renewal and seeding capacities (Barnhart and Simon 2007; Croker and Allan 2008; Hambardzumyan et al. 2008; Visvader and Lindeman 2008) . While the cellular origin of CSC/CIC and the associated molecular pathways are still matter of discussion, the existence of a small tumor cell subpopulation capable of initiating and maintaining tumor growth and initiating metastasis is being increasingly documented and accepted (Rossi et al. 2008; Tan et al. 2006) . Furthermore, evidence indicates that CSC/ CIC are more resistant to classical therapeutic approaches (i.e. chemotherapy and radiotherapy) compared to the bulk of the tumor cell mass. The mechanism of resistance remains largely elusive and might include the increased expression of multi-drug resistance-type of membrane transporters or a protective eVect of the microenvironment. Initial evidence for the existence of CSC/CIC came from the hematopoietic system, where in acute myeloid leukemia rare leukemic (stem) cells with a CD34 + /CD38 ¡ phenotype were shown to eYciently initiate transplantable experimental tumors in mice (Blair and Pamphilon 2003) . Subsequently, it has been demonstrated that tumor cell subpopulations with similar features, but diVerent surface phenotypes, also exist in solid tumors (Ailles and Weissman 2007; Cho and Clarke 2008) . In all cases, CSC/CIC are distinguished from the somatic" tumor cell population, by their capacity to eYciently generate new tumors when implanted at low number in mice. Conversely, "somatic" cancer cells are not able to initiate tumor growth, even in high number, in the same in vivo preclinical models.
While the crucial role of the tumor microenvironment in controlling tumor progression and metastasis is now widely accepted, the formation of a specialized environment supporting CSC/CIC survival and growth (the CSC niche), its anatomical organization and the cellular and molecular mediators of these eVects, are still under investigation (Sneddon and Werb 2007) . The recent identiWcation of human normal brain cells with self-renewal potential (reported as neural stem cells) that populate the subventricular zone, has contributed to the characterization of their niche and to the subsequent identiWcation and characterization of brain tumor CSC/CIC and their niche. Brain tumor CSC/CIC are localized in a vascular niche that is supposed to provide factors promoting their self-renewal (Calabrese et al. 2007; Veeravagu et al. 2008) . Perturbation of this niche results in a compromised ability CSC/CIC to promote tumor growth within the brain (Gilbertson and Gutmann 2007; Gilbertson and Rich 2007) . These observations demonstrate the relevance of the vascular niche to tumor pathophysiology, and suggest the possibility to target the niche itself, and associated molecular events, to impinge on cancer stem cells for therapeutic purposes (Croker and Allan 2008) .
A still open issue in the Weld is the deWnition of CSC/ CIC through phenotypical markers allowing their accurate identiWcation and isolation from the bulk of the tumor cell population in human and experimental tumors (Cho and Clarke 2008; Visvader and Lindeman 2008) . Some markers have been proposed, including CD44 + /CD24 ¡ in breast cancer, or CD133 + in brain, colon and pancreatic tumors. CD133, however, is also expressed by many normal stem cells in hematopoietic, neural and epithelial tissues (Woodward and Sulman 2008) . Isolation of CSC/CIC from speciWc tumor types would allow their comparison with "somatic" cancer cells and open the way to the identiWcation or speciWc gene expression proWles responsible for the aggressive CSC/CIC phenotype, including resistance to therapy (Cho and Clarke 2008; Dean et al. 2005 ).
The premetastatic niche: A niche for CSC/CIC ?
To explain how cancer cells can migrate from a primary site to colonize speciWc distant sites to grow and form metastases, Stephen Paget proposed the "seed and soil" hypothesis more than a century ago (Ribatti et al. 2006 ). This theory was based on the observation that tumors do not metastasize randomly but rater at preferred sites. Paget proposed that the formation of metastasis depends both on the properties of the tumor cells (seed) as well as the permissive role of the environment (soil) at the distant site. This hypothesis by which cancer cells are able to survive and proliferate only at speciWc secondary sites where there is an ideal environment that releases molecular mediators suitable for that type of cancer cells, still represents a main conceptual model of metastasis in modern cancer research (Steeg 2007; Talmadge 2007) .
Metastasis formation itself is a multi-step process that require tumor cells to escape from the primary site, intravasate into the hematic or lymphatic circulation, migrate and extravasate into secondary organs (Christofori 2006; Steeg 2006) . Recent work has shed new light on the genetic, molecular and cellular basis of metastasis (Gupta and Massague 2006; Nguyen and Massague 2007) . CSC/CIC might represent the unique sub-population of cells with the potential to successfully form metastasis in a distant organ (Li et al. 2007; Wicha 2006) . Metastasis formation, however, is a rather ineYcient process, mostly due to the need for a cancer cells to Wnd a proper microenvironment for initiating tumor growth in a secondary organ. It has been proposed that in order to form metastases, primary tumors might produce factors that induce the formation of a suitable and appropriate environment in the organ where metastasis will be seeded. This has lead to the concept of the premetastatic niche, whereby a special, permissive microenvironment in secondary target organs is induced over distance by the primary tumor (Kaplan et al. 2006b ). In this sense, there is a striking parallel between CSC/CIC maintenance and expansion in the primary tumor and formation of metastases in a distant organ. Both events require a particular niche or microenvironment and might share many cues promoting self-renewal ability, migration and invasion, resistance to apoptosis, and increased resistance to cytotoxic drugs. The Wrst in vivo experimental evidence that metastatic seeding requires the formation of a niche was the discovery that VEGFR-1 + BMDC colonize target organs to form tumorspeciWc premetastatic sites, before the arrival of the metastatic tumor cells themselves (Kaplan et al. 2005) . In these sites BMDC express several hematopoietic markers, such as CD34, CD116, c-kit, Sca-1, as well as integrins (e.g. 4 1), chemokines and chemokine receptors (e.g. CXCL12/CXCR4), promoting either their homing to the target tissue or recruitment and attachment of tumor metastatic cells, or both. Among the chemokines involved in tumor metastasis, the CXCL12 (also known as SDF-1 or stromal-derived factor)/CXCR4 axis plays a critical role in stem cell migration (Petit et al. 2007 ). Activation of CXCR4 induces motility, chemotactic response, adhesion, secretion of MMPs and release of angiogenic factors, such as VEGF-A. Interestingly this premetastatic niche, like the normal niche, is characterized by the presence of speciWc ECM proteins, such as Wbronectin, a ligand for 4 1 expressed on VEGFR-1 + cells. Thus, it appears that in order to survive at distant sites, disseminating tumor cells need to recreate a supportive microenvironment similar to the one formed in the primary tumor. One eYcient way to do it is by directing BMDC or immune/inXammatory cells to these distant sites of future metastasis . The chemoattractant proteins S100A8 and S100A9 were the Wrst factors shown to instruct the formation of the premetastatic niche (Hiratsuka et al. 2008; Kaplan et al. 2006b ). Additional studies are needed to further elucidate the biological mechanisms involved in the formation of this premetastatic niche, in particular regarding the identiWcation of the molecular mechanism responsible for the development of clinically relevant metastases from the initial seeds. The unraveling of such mechanisms could be useful for the development of a more accurate knowledge about the metastatic process, with major clinical implications to the prevention, monitoring and management of metastatic tumor spreading (Steeg and Theodorescu 2008) .
Therapy-induced modiWcation of the tumor environment impacts tumor progression
It is generally assumed that tumor escape and progression toward metastasis during or after therapy is due to the appearance of resistant tumor cells through a combination of therapy-induced genetic instability and subsequent clonal selection of the most Wtted cell. This assumption appears particularly relevant to radiotherapy, since the antitumor eVect of radiotherapy on tumor cells involve double strand DNA breaks (Gudkov and Komarova 2003) . Most cells with damaged DNA undergo p53-mediated apoptosis, mitotic cell death or senescence-like irreversible growth arrest. However, surviving cells might have increased genomic instability and mutations due to mismatched DNA repair and have the potential to rapidly evolve toward a more aggressive phenotype. Recent Wndings indicate that radiotherapy also rapidly and persistently alters the tissue microenvironment. These modiWcations aVect cell phenotype, tissue metabolism, bidirectional interactions and signaling events between cells (BarcellosHoV et al. 2005) . While there is evidence indicating that these changes might contribute to the antitumor eVects of radiotherapy, for example by creating a Wbrotic scar tissue restraining tumor invasion, there are also clinical and experimental observations indicating that irradiated stroma might exert tumor-promoting eVects (Barcellos-HoV et al. 2005) . Experimentally, tumors growing within a preirradiated stroma have reduced growth but show more invasive and metastatic phenotype, an eVect known as the tumor bed eVect (Milas et al. 1987 (Milas et al. , 1988 . Clinically, while adjuvant radiotherapy signiWcantly improves local tumor control (Bartelink et al. 2001) , tumor recurrences within a preirradiated Weld are associated with higher risk of local invasion and metastasis and poor prognosis compared to recurrences outside the irradiated area (O'Brien et al. 1986; Suit 1992; Vicini et al. 2003; Vikram et al. 1984) . We have recently reported that tumors growing in a preirradiated bed have reduced angiogenesis and are more hypoxic compared to control tumors (Monnier et al. 2008) . Tumor cells derived from these hypoxic tumors retain an invasive behavior in vitro and metastatic capacities in vivo, even after prolonged in vitro culture. A similar phenotype was observed when tumor cells were selected through repeated cycles of hypoxia in vitro, demonstrating that hypoxia was suYcient for the selection of resistant cells. Through gene expression proWling and gain and loss of function experiments, we identiWed the matricellular protein CYR61 and the integrin adhesion receptor V 5, as proteins cooperating in mediating survival under hypoxic condition, invasion and metastasis. Importantly, pharmacological inhibition of V 5 with a small molecular V integrin inhibitor EMD121974 (cilengitide) (Smith 2003) and an anti-V antibody, suppressed invasion and metastasis induced by CYR61 and attenuated metastasis of tumors growing within a preirradiated Weld in a cell autonomous manner. Based on these Wndings, we propose a model in which irradiation impairs the ability of the tumor stroma to elicit an eVective angiogenic response, and that tumors growing within this angiogenesis-deWcient stroma develop sustained hypoxia, which in turn, acts as a strong factor to select for hypoxia resistant, invasive and metastatic cells. Irradiated stroma itself might also actively contribute to create a microenvironment favoring tumor cell survival, invasion and metastasis. The radiation therapy response of the tumor microenvironment comprises an increased secretion or activation of many antiapoptotic (e.g. insulin-like growth factor-1) and pro-inXammatory cytokines (e.g. GM-CSF), or tumor promoting factors, such as EGF, G-CSF, FGF or TGF-. Some of the tumor-promoting eVects of irradiated stroma may be indirect though the recruitment of BMDC from peripheral blood, further boosting and sustaining the microenvironment itself.
Furthermore, there are emerging data on CSC/CIC and resistance to radiation therapy: this radioresistant sub-population within the tumor mass shows a 50% lower dosedependent formation of reactive oxygen species in response to radiation and reduced or even absent double-strand DNA breaks. In a breast cancer experimental model, CSC/CIC (as deWned by the CD44 + /CD24 ¡ phenotype) derived from MCF-7 and MDA-MB-231 human cancer lines were isolated and exposed to a single dose of radiation. These cells were more resistant to radiation therapy, had few or no double-strand DNA breaks, and a 50% decrease in dose-dependent formation of reactive oxygen species, compared to the bulk of cancer cell population (Phillips et al. 2006) . In another study, CD133 + CSC/CIC isolated from glioma showed increased survival after radiation treatment as compared to the CD133 ¡ cells, preserving the tumor-forming ability and aggressive phenotype of the non-irradiated CD133 + cells (Chiou et al. 2008) . CSC/CIC appear to survive better and to repair DNA more eYciently compared to the bulk of the tumor cell population, and this in turn could make the tumor more resistant to radiotherapy. Thus, radiotherapy might modify the microenvironment in a way to favor the survival of CSC/CIC, thereby explaining the increased aggressive behavior of tumors recurring within a preirradiated bed. The contribution of tumor microenvironment to promote survival of CSC/CIC could represent a novel therapeutic target to prevent or manage cancer recurrences after radiotherapy.
Conclusions
In recent years the study of tumor microenvironment, its cellular and molecular components, and how they can aVect neoplastic progression, has become an emerging topic in cancer research. Factors released by the tumor cells themselves, in particular pro-/antiinXammatory molecules or pro-/antiangiogenic mediators, and factors polarizing immune surveillance toward a tumor-permissive or tumorrejecting phenotype contribute in creating an environment mostly friendly and sometimes hostile to the tumor. Importantly, events and molecules implicated in this cross talk within the tumor microenvironment have emerged as attractive targets in anticancer therapeutic intervention.
The introduction in the clinic of antiangiogenic drugs has been widely recognized as a major breakthrough in biomedical research and clinical oncology. This represents a proof-of-concept indicating that targeting stromal events can impact tumor progression. More recent works suggest that stromal events may also modulate the response of cancer cells to therapeutic interventions targeting the tumor cells themselves, in particular chemotherapy, and may contribute to the emergence of resistance to therapy. While several mechanisms of resistance to antiangiogenic treatments have been proposed, there is a limited knowledge on how tumor cells and the microenvironment respond, adapt and evolve under this therapeutic approach.
Taken together, these Wndings emphasize the need to further unravel the complex molecular networks and cross talk between diVerent components of the tumor microenvironment and the tumor cells itself. A deepened knowledge on mechanisms involved in tumor progression and invasiveness toward metastasis could be essential to improve eYcacy of current therapeutic interventions with signiWcant clinical impact.
